Idylla™ Product Features


Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime. Idylla™ covers the entire process from sample to result in a time frame of 35 to 150 minutes with less than 2 minutes hands-on time. Idylla™ is applicable for a wide range of clinical sample types and can analyze both RNA and DNA. The fully integrated system enables clinical laboratories to perform a broad range of applications in oncology, infectious diseases and beyond.


Idylla™ and the system’s first assay, the Idylla™ BRAF Mutation Test, have obtained CE-IVD marking.


  • Less than 2 minutes hands-on time per sample
  • Applicable for a wide variety of clinical sample types: FFPE tissue slices, macrodissectedmaterial, blood, urine, stool, sputum or tissue
  • No manual deparaffinization required
  • All reagents integrated in the cartridge
  • Intuitive, touchscreen-based, user interface
  • Only limited training needed
  • Real-time support and updates



Run a test when needed: anytime, anywhere

  • Access on-demand, no need for batching
  • Up to 8 separately operating instruments per console

Any clinical lab

  • Scalable set-up to cover low and high throughput needs
  • Full automation
  • Only limited training needed
  • Fits into any workflow, 24/7
  • Compact platform design

Rapid results

Better, faster services for clinicians and patients

  • Less than 2 minutes hands-on time
  • Turnaround-time between 35 and 150 minutes
  • Access on-demand
  • Bidirectional connectivity with laboratory or hospital information management systems

Contamination-controlled design

  • Liquid-tight, disposable cartridges
  • Strong reduction of risk of contamination
  • No need for separate pre- or post PCR labs

RNA & DNA analysis

Fully automated, real-time PCR

  • Qualitative and quantitative results for DNA and RNA.
  • Combination of proprietary and versatile sample preparation technology with state-of-the-art multiplexed real-time PCR amplification and detection.
  • For the detection of SNPs, mutations, translocations or changes in RNA expression profile



More answers from one sample

  • Simultaneous detection of up to 30 molecular targets in a single cartridge in standard mode.
  • Specific test protocols under development for the detection of more than 30 biomarkers per sample.
  • Specifically relevant for oncology where sample material is often limited.



A broad menu


  • Biocartis’ main focus are oncology & infectious diseases
  • Within oncology the Idylla™ BRAF Mutation Test and the Idylla™ KRAS were the first launched CE-IVD marked tests
  • The NRAS-BRAF-EGFRS492R assay is launched for research use only
  • Biocartis launched the first and only fully automated ctBRAF liquid biopsy assay
  • The Idylla™ Respiratory (IFV-RSV) panel - developed by Janssen – is the first CE-IVD test launched in infectious diseases